StocksMediumUpdated×3•Originally published 4 November 2026•Updated 5 November 2026•
1 min read
ADMA Biologics Stock Surges 23% on Strong ASCENIV Demand and Earnings Beat
Key Facts
1ADMA Biologics reported adjusted earnings per share of $0.23 for the third quarter of 2026.
2The company's revenue reached $141.1 million during the third quarter.
ADMA Biologics stock surged 23% driven by a 31% increase in demand for its drug ASCENIV. The rally followed the company's report of earnings at $0.22 per share for the third quarter of 2026, surpassing analyst estimates of $0.19.
Total revenue for the quarter reached $141.1 million according to Benzinga reports. ADMA was trading at $11.11 on November 3, 2026, within a session range of $10.7 to $11.44.
Latest Updates · 1
- Notable·
Update: The company's results exceeded analyst estimates, with earnings per share coming in $0.03 higher than expected. Total revenue also surpassed analyst projections for the third quarter of 2026.